



(51) International Patent Classification:

A61K 38/04 (2006.01) A61P 1/00 (2006.01)

A61K 38/12 (2006.01)

(21) International Application Number:

PCT/US2021/012842

(22) International Filing Date:

08 January 2021 (08.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/959,854 10 January 2020 (10.01.2020) US

(71) Applicant: PROTAGONIST THERAPEUTICS, INC.

[US/US]; 7707 Gateway Boulevard, Suite 140, Newark, California 94560-1160 (US).

(72) Inventors; and

(71) Applicants: GUPTA, Suneel Kumar [US/US]; 1331 Elsona Drive, Sunnyvale, California 94087 (US). MODI, Nishit Bachulal [US/US]; 587 Torland Court, Sunnyvale, California 94087 (US).

(72) Inventors: CHENG, Xiaoli; 263 Lassen Avenue, Mountain View, California 94043 (US). LIU, David Y.; 201 Ferne Ave, Palo Alto, California 94306 (US).

MATTHEAKIS, Larry C.; 20612 Sunrise Drive, Cupertino, California 95014 (US).


(74) Agent: LAHERTY, Carol D. et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH $\alpha 4 \beta 7$ INTEGRIN ANTAGONISTS

FIG. 22



(57) **Abstract:** The invention relates to methods of treating inflammatory bowel diseases, including with engineered peptides (e.g. peptide monomers and dimers comprising disulfide or thioether intramolecular bonds) that bind $\alpha 4 \beta 7$ integrin. In one aspect, the disclosure provides a method of treating an inflammatory bowel disease (IBD) in a subject in need thereof, comprising administering to the subject an $\alpha 4 \beta 7$ integrin antagonist, wherein the antagonist is administered to the patient orally at a dose of about 100 mg to about 500 mg, once or twice daily, wherein the antagonist is a peptide dimer compound comprising two peptides, or a pharmaceutically acceptable salt thereof.

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))